Press Release
ELC Group partners with mdi Europa GmbH to offer end-to-end regulatory solution for medical device companies in Europe
Preferred Partnership delivers complete consultancy support and expertise – from device registration to CE marking
Cambridge, UK, June 6 2012 – ELC GROUP, the pan-European pharmaceutical regulatory affairs organisation, today announces that it has formed a preferred European partner relationship with mdi Europa GmbH, a global regulatory consultancy for medical device and IVD companies. The two companies are partnering to provide a complete, end-to-end regulatory solution for medical device manufacturers in Europe – spanning initial device registration and documentation to CE marking and post-marketing services.
ELC Group has developed a strong track record and extensive expertise in medical device regulatory services, including regulation strategy, Medical Device Directive consultancy, device registration, and full technical file preparation. Through its Preferred Partnership arrangement with mdi Europa, ELC Group is now able to offer a one-stop, full-service consultancy solution to medical device manufacturers, focused on speeding time-to-market and easing the compliance process. With this new total service solution, ELC Group’s strengths in documentation support are complemented by mdi Europa’s skills in guiding companies to achieving CE certification and approvals, plus post-marketing device vigilance.
Commenting on today’s announcement, Marco Rubinstein, CEO of ELC Group said: “By joining hands with a regulatory organisation of the calibre of mdi Europa, we are offering our customers a true best-in-class solution for end-to-end medical device compliance. The breadth of this combined solution means that customers can benefit from a smoother regulatory process and faster time-to-market, all in the confidence that they are getting the very highest quality consultancy, support and advice available.”
mdi Europa Vice President Operations, Martina Sander-Giesemann, added: “It was most important for us to find a partner that has an equal understanding of customer service. With ELC Group, we have found an experienced, well-positioned partner that focuses on customer needs in the same way as we do. Regulatory compliance is often felt to be a burden – together with ELC Group, we do our utmost to take this burden off our mutual clients.”
ELC Group helps clients expedite time-to-market through a broad range of development capabilities, integrated advanced technologies, regulatory affairs consulting, and commercialisation services. ELC Group delivers its customised solutions through four core business segments: Regulatory Affairs Services; Medical Devices; EU REACH (Registration, Evaluation and Authorisation of Chemicals) Regulation Services; and Corporate Languages Solutions (Translations, Design, DTP, Localisation).
Press contacts
Akhil Jain
ELC Group
ajain [at] elc-group [dot] com
Phone: +420 22 491 00 00
Nicky Denovan
EvokedSet PR
nicky[at] evokedset [dot] com
Phone: +44 (0)7747 017654
About ELC Group
ELC GROUP is a leading global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries as well as REACH services to the Chemical industry. It helps companies that lack the resource (skills and knowledge) to cost effectively deliver regulatory affairs.
ELC Group provides full-service, multi-lingual consulting and cost-effective solutions to regulatory approvals using experts with in-depth knowledge and experience throughout the world. The team ranges from former FDA investigators to individuals with over 30 years of industry experience with broad capabilities. This includes integrated advanced technologies, regulatory affairs consulting and commercialisation services.
About mdi Europa GmbH
mdi Europa is a regulatory affairs consulting company specializing in CE-marking and regulatory affairs for both the medical and in vitro diagnostic medical device manufacturing industry. Its predominant role is that of “authorized representative”; a prerequisite for all non-European manufacturers without a subsidiary / place of business within the European Union. Services include labeling review, product registration, post market surveillance, product classification, vigilance, language requirements and general guidance in interpreting the Directives 90/385/EEC, 93/42/EEC & 98/79/EEC. For more information, visit www.mdi-europa.com
Also see our
press coverage
News Index
11 Feb 2019
Garth Hedenskog joins ELC Group to expand global sales
26 Nov 2018
Industry plans for disruption amid Brexit uncertainty
25 Oct 2018
ELC Group at 5th Nordic Pharmacovigilance Day - Oct 24th, Copenhagen
05 Oct 2018
EU/US MRA - Brief overview and update
21 Aug 2018
Brexit - has the music stopped?
13 Jul 2018
15 Jun 2018
08 May 2018
MHRA sets its post-Brexit strategic direction
12 Apr 2018
20 Mar 2018
Clinical Trials: all change 2019
22 Jan 2018
Orphan Medicines: almost 20 years on
15 Dec 2017
05 Oct 2017
How recent moves by the FDA spell good news for generics in the US
11 Sep 2017
Medicines for the Elderly – is your drug development strategy up to the mark?
14 Aug 2017
The MNAT initiative – what’s new?
19 Jul 2017
ICH Q12: Light at the end of the tunnel…?
05 Jun 2017
Q3D: Are your established products in compliance?
02 Jun 2017
Key pharmacovigilance trends to watch
08 May 2017
10 Apr 2017
New EMA Consultation on the Quality of Inhaled Pharmaceutical Products
16 Mar 2017
European Parliament’s adoption of ‘Options for improving access to medicines’ procedure
16 Feb 2017
Article 58: a hidden potential
24 Jan 2017
Global lifesciences partner ELC Group teams with PSR Group for advanced drug development
19 Jan 2017
A positive step forward for Biosimilar registration
20 Dec 2016
Falsified Medicines Directive – Are you making the right preparations?
21 Nov 2016
New Public consultation launched by the European Commission (EC)
19 Oct 2016
Transatlantic collaboration to boost research and development of medicines for rare diseases
03 Jun 2016
ELC Group to showcase regulatory affairs solutions at CPhI events in Shanghai and Barcelona
16 Jun 2015
ELC Group in early-stage development of novel influenza vaccine
09 Jun 2015
ELC Group expands into pharmaceutical product development market
21 Apr 2015
ELC Group signs 1.5 million Euro regulatory affairs contract with Chinese pharma giant
24 Feb 2015
02 Feb 2015
ELC GROUP to present at “Regulatory & Legal Affairs in Russia 2015” Conference
15 Sep 2014
20 Aug 2014
ELC Group Appoints Dr. Siddharth Chachad as Head of Global Clinical Development and Medical Affairs
28 Jul 2014
ELC Group Appoints Head of Regulatory Affairs for Russia and CIS
14 Apr 2014
10 Oct 2013
17 Sep 2013
Global regulatory affairs specialist ELC Group appoints former MHRA Expert Medical Assessor
23 Apr 2013
27 Feb 2013
Global regulatory affairs specialist ELC Group to deliver pharmaceutical training event in Latvia
20 Feb 2013
Global pharmaceutical regulatory affairs specialist ELC Group launches Clinical Trials services
10 Jan 2013
31 Dec 2012
07 Nov 2012
Global pharmaceutical regulatory affairs specialist ELC Group establishes new office in Singapore
22 Aug 2012
12 Jun 2012
XEVMPD software provider Pharma eReport launches Excel Data Import Service
06 Jun 2012
28 Mar 2012
ELC Group joins DIA EuroMeeting in Copenhagen
21 Mar 2012
08 Mar 2012
ELC Group Hosts Successful International Regulatory Seminar
06 Mar 2012
Pharmaceutical regulatory affairs specialist ELC Group opens new office in Mumbai
23 Feb 2012
Regulatory challenges for 2012 and their impact on marketing authorisation
21 Feb 2012
08 Feb 2012
Pharmaceutical regulatory affairs specialist ELC Group establishes global HQ in Cambridge, UK
07 Dec 2011
27 Sep 2011
12 Jul 2011
ELC Group aim to foster strategic and economic ties within India and China
25 May 2011
ELC Group announces doubled revenues
11 May 2011